MCID: AST005
MIFTS: 81

Asthma

Categories: Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Asthma

MalaCards integrated aliases for Asthma:

Name: Asthma 54 38 12 50 71 71 29 52 41 3 42 14 69
Chronic Obstructive Asthma 12 52 69
Bronchial Hyperreactivity 12 52 69
Asthma, Diminished Response to Antileukotriene Treatment in 54 13
Chronic Obstructive Asthma with Acute Exacerbation 12
Chronic Obstructive Asthma with Status Asthmaticus 12
Asthma, Protection Against 54
Asthma, Susceptibility to 29
Asthma, Exercise-Induced 69
Exercise Induced Asthma 12
Exercise-Induced Asthma 12
Asthma Exercise-Induced 52
Asthma, Nocturnal 54
Bronchial Asthma 71

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant vs. multifactorial


Classifications:



Summaries for Asthma

MedlinePlus : 41 asthma is a chronic disease that affects your airways. your airways are tubes that carry air in and out of your lungs. if you have asthma, the inside walls of your airways become sore and swollen. that makes them very sensitive, and they may react strongly to things that you are allergic to or find irritating. when your airways react, they get narrower and your lungs get less air. symptoms of asthma include wheezing coughing, especially early in the morning or at night chest tightness shortness of breath not all people who have asthma have these symptoms. having these symptoms doesn't always mean that you have asthma. your doctor will diagnose asthma based on lung function tests, your medical history, and a physical exam. you may also have allergy tests. when your asthma symptoms become worse than usual, it's called an asthma attack. severe asthma attacks may require emergency care, and they can be fatal. asthma is treated with two kinds of medicines: quick-relief medicines to stop asthma symptoms and long-term control medicines to prevent symptoms. nih: national heart, lung, and blood institute

MalaCards based summary : Asthma, also known as chronic obstructive asthma, is related to churg-strauss syndrome and dengue disease, and has symptoms including coughing, cyanosis and dyspnea. An important gene associated with Asthma is IL13 (Interleukin 13), and among its related pathways/superpathways are Asthma and Innate Immune System. The drugs Accolate and Advair have been mentioned in the context of this disorder. Affiliated tissues include Lung, lung and testes, and related phenotypes are immune system and respiratory system

Disease Ontology : 12 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has symptom recurring periods of wheezing (a whistling sound while breathing), has symptom chest tightness, has symptom shortness of breath, has symptom mucus production and has symptom coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.

NIH Rare Diseases : 50 asthma is a breathing disorder that affects the airways. people with this condition experience recurrent swelling and narrowing of the airways of the lungs which is associated with wheezing, shortness of breath, chest tightness, and coughing. most affected people have episodes of symptoms ("asthma attacks") followed by symptom-free periods; however, some may experience persistent shortness of breath in between attacks. asthma is considered a complex or multifactorial condition that is likely due to a combination of multiple genetic, environmental, and lifestyle factors. many people with asthma have a personal or family history of allergies, such as hay fever or eczema. having a family member with asthma is associated with an increased risk of developing the condition. treatment generally includes various medications, both to prevent asthma attacks and to provide quick relief during an attack. last updated: 2/28/2016

OMIM : 54
Bronchial asthma is the most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, and dyspnea; bronchial hyperresponsiveness (BHR) as assessed by methacholine challenge test; serum IgE levels; atopy; and atopic dermatitis (Laitinen et al., 2001; Illig and Wjst, 2002; Pillai et al., 2006). See 147050 for information on the asthma-associated phenotype atopy. (600807)

CDC : 3 Asthma is a disease that affects your lungs. It causes repeated episodes of wheezing, breathlessness, chest tightness, and nighttime or early morning coughing. Asthma can be controlled by taking medicine and avoiding the triggers that can cause an attack. You must also remove the triggers in your environment that can make your asthma worse.

Novus Biologicals : 53 Asthma is a chronic lung disease that causes inflammation, thickening and narrowing of airways, as well as an overproduction of mucus. More than 300 million people worldwide suffer from asthma. Asthma symptoms include wheezing, shortness of breath, coughing and tightness of the chest. Interleukin 13 (IL-13) is the key effector cytokine in asthma. IL-13 stimulates airway fibrosis via action of matrix metalloproteinases (MMPs) on tumor transforming growth factor beta (TGN-beta), and also promotes epithelial damage, mucus production and an increased concentration of eosinophils. The inflammatory response characteristic of asthma is augmented by the production of IL-13 and other TH2 cytokines.

UniProtKB/Swiss-Prot : 71 Asthma: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.

Wikipedia : 72 Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by... more...

Related Diseases for Asthma

Diseases in the Asthma family:

Asthma 2 Asthma 1

Diseases related to Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 467)
id Related Disease Score Top Affiliating Genes
1 churg-strauss syndrome 33.3 IL4 IL5 TNF
2 dengue disease 33.0 IL13 IL4 IL5 TNF
3 acute chest syndrome 32.2 ADAM33 ADRB2 CCL11 CYSLTR1 IL13 IL4
4 lymphoma 31.7 IL13 IL4 IL5 TNF
5 tracheal stenosis 31.5 CCL11 IL9 TNF
6 malaria 31.2 CCL11 IL13 IL4 IL5 IL9 TNF
7 nut allergy 30.9 IL4 IL5 RNASE3
8 glioblastoma multiforme 30.9 IL5 RNASE3 TNF
9 allergic asthma 12.4
10 asthma, aspirin-induced 12.3
11 asthma 2 12.2
12 asthma 1 12.2
13 intrinsic asthma 12.2
14 asthma susceptibility 5 12.1
15 asthma-related traits 7 12.1
16 cough variant asthma 12.1
17 asthma-related traits 4 12.0
18 asthma-related traits 3 12.0
19 asthma-related traits 6 12.0
20 asthma-related traits 8 11.7
21 asthma susceptibility, il13-related 11.7
22 asthma susceptibility, muc7-related 11.7
23 asthma susceptibility, phf11-related 11.7
24 asthma susceptibility, pla2g7-related 11.7
25 asthma susceptibility, scgb3a2-related 11.7
26 asthma susceptibility, tnf-related 11.7
27 asthma susceptibility, adrb2-related 11.7
28 asthma susceptibility, ccl11-related 11.7
29 asthma susceptibility, hla-g-related 11.7
30 asthma susceptibility, hnmt related 11.6
31 spontaneous ocular nystagmus 11.6 ADAM33 ADRB2 ALOX5 CCL11 CYSLTR1 IL13
32 combined oxidative phosphorylation deficiency 8 11.6 ADRB2 HAVCR1 IL13 IL4 IL4R IL5
33 status asthmaticus 11.6
34 intracranial hypertension 11.6 ADAM33 CCL11 IL13 IL4 IL4R IL5
35 malignant epithelial mesothelioma 11.5 CCL11 CYSLTR1 HAVCR1 IL13 IL4 IL4R
36 pseudohypoaldosteronism, type iid 11.5 ALOX5 CCL11 HAVCR1 IL13 IL4 IL4R
37 dehydration polycythemia 11.5 CCL11 CYSLTR1 IL13 IL4 IL5 RNASE3
38 pelvic varices 11.5 CCL11 CYSLTR1 IL13 IL4 IL5 RNASE3
39 inner ear disease 11.5 CCL11 IL13 IL4 IL4R IL5 RNASE3
40 mediastinum neurofibroma 11.5 CCL11 IL13 IL4 IL4R IL5 IL9
41 eyelid neoplasm 11.5 CCL11 CYSLTR1 IL13 IL4 IL5 RNASE3
42 benign mammary dysplasia 11.5 CCL11 IL13 IL4 IL5 RNASE3 TNF
43 fuchs' heterochromic uveitis 11.5 CCL11 IL13 IL4 IL5 RNASE3 TNF
44 ragweed sensitivity 11.5 CCL11 IL13 IL4 IL5 RNASE3 TNF
45 autoimmune neuropathy 11.5 ADRB2 IL13 IL4R IL5 RNASE3
46 epidermolysis bullosa 11.5 CCL11 IL13 IL4 IL5 NPSR1 RNASE3
47 epithelioid type angiomyolipoma 11.5 CCL11 IL13 IL4 IL5 RNASE3 TNF
48 trachea leiomyoma 11.5 CCL11 IL13 IL4 IL5 RNASE3
49 viljoen kallis voges syndrome 11.5 CCL11 IL13 IL4 IL5 RNASE3
50 angiomyoma 11.5 CCL11 IL13 IL4 IL5 RNASE3

Comorbidity relations with Asthma via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease

Graphical network of the top 20 diseases related to Asthma:



Diseases related to Asthma

Symptoms & Phenotypes for Asthma

Symptoms via clinical synopsis from OMIM:

54

Resp:
asthma
airway hyperresponsiveness


Clinical features from OMIM:

600807

Human phenotypes related to Asthma:

32
id Description HPO Frequency HPO Source Accession
1 asthma 32 HP:0002099

UMLS symptoms related to Asthma:


coughing, cyanosis, dyspnea, snoring, spasm, wheezing, expiratory wheeze, labored breathing

MGI Mouse Phenotypes related to Asthma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.77 HLA-G IL13 IL4 IL4R IL5 IL9
2 respiratory system MP:0005388 9.23 CCL11 CYSLTR1 IL13 IL4 IL4R IL5

Drugs & Therapeutics for Asthma

FDA approved drugs:

(show all 16)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Accolate 17 ZAFIRLUKAST AstraZeneca September 1999|October 1996
2
Advair 17 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
3
Alvesco 17 CICLESONIDE Nycomed January 2008
4
Arnuity Ellipta 17 FLUTICASONE FUROATE GlaxoSmithKline August 2014
5
Azmacort 17 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
6
Dulera 17 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
7
Flovent Rotadisk 17 FLUTICASONE PROPIONATE GlaxoSmithKline November 1997
8
Foradil Aerolizer 17 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Metaprotereol Sulfate 17 METAPROTERENOL SULFATE Morton Grove Pharmaceuticals March 1997
10
Nucala 17 MEPOLIZUMAB GlaxoSmithKline November 2015
11
Qvar 17 BECLOMETHASONE DIPROPIONATE Ivax May 2002
12
Rayos 17 PREDNISONE Horizon Pharma July of 2012
13
Serevent 17 SALMETEROL XINAFOATE GlaxoSmithKline September 1997
14
Singulair 17 MONTELUKAST SODIUM Merck February 1998
15
Xolair 17 OMALIZUMAB Genentech June 2003
16
Zyflo 17 ZILEUTON Abbott Laboratories January 1997

Drugs for Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1093)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51333-22-3 63006 5281004
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
3
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
4
Procaterol Approved Phase 4,Phase 3,Phase 2,Phase 1 72332-33-3 688561
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 299-42-3 9294
6
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
7
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90-82-4 7028
8
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 158966-92-8 5281040
9
Dexlansoprazole Approved Phase 4,Phase 3,Phase 2 138530-94-6, 103577-45-3 9578005
10
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 103577-45-3 3883
11
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
12
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
13
Etomidate Approved Phase 4,Phase 2,Phase 3 33125-97-2 36339 667484
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 437-38-7 3345
15
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2 59467-70-8 4192
16
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 2078-54-8 4943
17
Remifentanil Approved Phase 4 132875-61-7 60815
18
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 242138-07-4
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-24-8 5755
21
Terbutaline Approved Phase 4,Phase 3,Phase 2,Phase 1 23031-25-6 5403
22
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
23
Bambuterol Approved Phase 4,Phase 1 81732-65-2, 81732-46-9 54766
24
Azelastine Approved Phase 4,Phase 3,Phase 2,Phase 1 58581-89-8 2267
25
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
26
Xylometazoline Approved Phase 4,Phase 3 526-36-3 5709
27
Capsaicin Approved Phase 4,Phase 2,Early Phase 1 404-86-4 1548943
28
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
29 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 26787-78-0 33613 2171
31
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83881-51-0 2678
32
Cilostazol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 73963-72-1 2754
33
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
34
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 69-65-8 453 6251
35
Carvedilol Approved, Investigational Phase 4,Phase 1 72956-09-3 2585
36
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
37
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1 22254-24-6, 60205-81-4 43232
38 Beractant Approved Phase 4 108778-82-1
39
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
40
Prilocaine Approved Phase 4 721-50-6 4906
41
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474
42
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1 74103-06-3, 66635-83-4 3826
43
Desflurane Approved Phase 4 57041-67-5 42113
44
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
45
Atropine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 5908-99-6, 51-55-8 174174
46
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 3,Phase 1 439-14-5 3016
47
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 6740-88-1 3821
48
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
49
Aminocaproic Acid Approved, Investigational Phase 4 60-32-2 564
50
Probucol Approved Phase 4,Phase 2 23288-49-5 4912

Interventional clinical trials:

(show top 50) (show all 6304)

id Name Status NCT ID Phase Drugs
1 Assessing Decision Maker Tools for Asthma: the Asthma APGAR Unknown status NCT01446315 Phase 4
2 Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence Unknown status NCT02045875 Phase 4 Dulera
3 Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home Unknown status NCT01783132 Phase 4
4 Vitamin D for the Treatment of Severe Asthma Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
5 Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma. Unknown status NCT01939951 Phase 4
6 Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Unknown status NCT02053402 Phase 4 Vitamin D
7 A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children Unknown status NCT00624429 Phase 4 Budesonide respules
8 Inflammatory, Functional and Image Composite Measure to Define Asthma Control Unknown status NCT00597064 Phase 4 prednisone
9 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
10 Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
11 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4 fluticasone/ salmeterol;fluticasone
12 Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA) Unknown status NCT01170429 Phase 4 Procaterol hydrochloride;Meptin placebo
13 Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma Unknown status NCT01584804 Phase 4 Su-Huang antitussive capsule;Sugar pill
14 Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma Unknown status NCT01404013 Phase 4 ICS/LABA;Montelukast;ICS/LABA and Montelukast
15 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
16 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
17 Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia Unknown status NCT02289391 Phase 4 Anesthesia induction;Anesthesia maintenance;Assisted anesthesia
18 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
19 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
20 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
21 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
22 Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis Unknown status NCT02345993 Phase 4 Extra fine Formoterol/Beclomethasone
23 Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery Unknown status NCT02110654 Phase 4 Montelukast;mometasone furoate nasal spray
24 Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children Unknown status NCT00172341 Phase 4 Staloral TM
25 Concentrations of Salmeterol in Blood and Urine Unknown status NCT00914901 Phase 4 inhaled salmeterol
26 Terbutaline Concentrations in Blood and Urine Unknown status NCT00914797 Phase 4 inhaled and oral terbutaline
27 Concentrations of Formoterol in Blood and Urine Unknown status NCT00914654 Phase 4 inhaled formoterol
28 Rapid Onset Action of Salbutamol Versus Formoterol Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
29 Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics Unknown status NCT02574975 Phase 4 methacholine;adenosine monophosphate;leukotriene D4;budesonide /formoterol
30 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
31 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control Unknown status NCT00385359 Phase 4 Albuterol
32 Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids Unknown status NCT00397267 Phase 4 inhalation of corticosteroids
33 The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma Unknown status NCT02002754 Phase 4 Bambuterol Hydrochloride tablets
34 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
35 Predicting the Clinical Response to Omalizumab With Anti-IgE Ab Response or Syk Expression in Basophils Unknown status NCT02023151 Phase 4 Omalizumab;Placebo injection
36 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
37 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
38 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
39 POLlinosis and Exhaled Breath Temperature Unknown status NCT01785394 Phase 4 5 grass allergen extract
40 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
41 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
42 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
43 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4 Montelukast;Placebo
44 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
45 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
46 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
47 Airway Clearance for Prevention of COPD Exacerbation Unknown status NCT00181207 Phase 4
48 Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication Unknown status NCT00424281 Phase 4 Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
49 Middle Meatal Bacteriology During Acute Respiratory Infection in Children Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid
50 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Unknown status NCT02371941 Phase 4 oral cromolyn sodium;Placebo

Search NIH Clinical Center for Asthma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Asthma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Asthma:
Bone marrow-derived mesenchymal stem cells for severe refractory asthma
Embryonic/Adult Cultured Cells Related to Asthma:
Mouse bone marrow-derived mesenchymal stem cells (family) PMIDs: 21653527 20801416

Cochrane evidence based reviews: asthma

Genetic Tests for Asthma

Genetic tests related to Asthma:

id Genetic test Affiliating Genes
1 Asthma, Susceptibility to 29
2 Asthma 29

Anatomical Context for Asthma

MalaCards organs/tissues related to Asthma:

39
Lung, Testes, Heart, T Cells, Neutrophil, Endothelial, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Asthma:
id Tissue Anatomical CompartmentCell Relevance
1 Lung Trachea Airway Smooth Muscle Cells Potential therapeutic candidate, affected by disease

Publications for Asthma

Articles related to Asthma:

(show top 50) (show all 6596)
id Title Authors Year
1
Hay fever, asthma, and eczema and early infectious diseases among children in Kilimanjaro, Tanzania. ( 28083975 )
2017
2
Parents' Childhood Socioeconomic Circumstances are Associated with their Children's Asthma Outcomes. ( 28089871 )
2017
3
Association of single-nucleotide polymorphisms in toll-like receptor 2 gene with asthma susceptibility: A meta-analysis. ( 28514297 )
2017
4
Estimation of Serum YKL-40 by Real-Time Surface Plasmon Resonance Technology in North-Indian Asthma Patients. ( 27616735 )
2017
5
[Characteristics of the expression of the transcription factor pSTAT3 in asthma]. ( 28378730 )
2017
6
Deficiency of KLF4 compromises the lung function in an acute mouse model of allergic asthma. ( 28867182 )
2017
7
Cost effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. ( 28532191 )
2017
8
PDCD1 PD-1.3 polymorphism and allergic bronchial asthma in Russian and Buryat patients. ( 27286421 )
2017
9
Successful treatment of pulmonary nocardiosis with fluoroquinolone in bronchial asthma and bronchiectasis. ( 28352469 )
2017
10
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. ( 28530840 )
2017
11
Association between perfluoroalkyl substance exposure and asthma and allergic disease in children as modified by MMR vaccination. ( 28091126 )
2017
12
Genotyping of IL-4 -590 (C>T) Gene in Iraqi Asthma Patients. ( 28386156 )
2017
13
Increased BAFF expression in nasal polyps is associated with local IgE production, Th2 response and concomitant asthma. ( 28035475 )
2017
14
Pulmonary Intravascular Large B-cell Lymphoma (IVLBCL) Disguised as an Asthma Exacerbation in a Patient with Asthma. ( 28717087 )
2017
15
Polymorphisms in DENND1B gene are associated with asthma and atopy phenotypes in Brazilian children. ( 28668455 )
2017
16
Asthma-related lung function, sleep quality, and sleep duration in urban children. ( 28526251 )
2017
17
Response to omalizumab in patients with severe allergic asthma: A real-life study. ( 28947015 )
2017
18
Association Between Asthma and Periodontal Disease: A Systematic Review and Meta-Analysis. ( 28871892 )
2017
19
Concomitant suppression of Th2 and Th17 cell responses in allergic asthma by targeting RORI^t. ( 28943467 )
2017
20
Staphylococcus aureus enterotoxin sensitization involvement and its association with the CysLTR1 variant in different asthma phenotypes. ( 28034578 )
2017
21
Traffic-related air pollution exposure is associated with allergic sensitization, asthma, and poor lung function in middle age. ( 27372567 )
2017
22
Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma. ( 28334838 )
2017
23
Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma. ( 28063043 )
2017
24
Saponin-enriched extract of Asparagus cochinchinensis alleviates airway inflammation and remodeling in ovalbumin-induced asthma model. ( 28949387 )
2017
25
Awareness about childhood asthma. ( 28948946 )
2017
26
Use of Medicaid and housing data may help target areas of high asthma prevalence. ( 27435833 )
2017
27
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. ( 28838980 )
2017
28
Correlation study of cough variant asthma and mycoplasma pneumonia infection in children. ( 28671088 )
2017
29
Soluble Fibre Meal Challenge Reduces Airway Inflammation and Expression of GPR43 and GPR41 in Asthma. ( 28075383 )
2017
30
The contribution of an asthma diagnostic consultation service in obtaining an accurate asthma diagnosis for primary care patients: results of a real-life study. ( 28526889 )
2017
31
Cockroach Allergy and Urban Asthma. ( 28528788 )
2017
32
The C5a/C5aR1 axis controls the development of experimental allergic asthma independent of LysM-expressing pulmonary immune cells. ( 28931049 )
2017
33
Prevalence of Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma at a tertiary care center in North India. ( 28360463 )
2017
34
Dupilumab for the treatment of asthma. ( 28085503 )
2017
35
Asthma-chronic obstructive pulmonary disease overlap syndrome - Literature review and contributions towards a Portuguese consensus. ( 28089081 )
2017
36
IL-37 a New IL-1 Family Member Emerges as a Key Suppressor of Asthma Mediated by Mast Cells. ( 27982737 )
2017
37
Sputum transcriptomics reveal up-regulation of IL-1 receptor family members in severe asthma. ( 28528200 )
2017
38
Corrigendum: Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. ( 28936430 )
2017
39
Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review. ( 28495938 )
2017
40
Maternal Folate Intake during Pregnancy and Childhood Asthma. ( 28084816 )
2017
41
Differential regulation of PD-1 and its ligands in allergic asthma. ( 28865147 )
2017
42
Atopy, asthma, and the elderly: A paradigm for personalized therapy. ( 28441985 )
2017
43
Prevalence, risk factors, and clinical outcomes of atopic and nonatopic asthma among rural children. ( 28087381 )
2017
44
The impact of inappropriate use of short acting beta agonists in asthma. ( 28947020 )
2017
45
Chlamydia pneumoniae Induces Interferon Gamma Responses in Peripheral Blood Mononuclear Cells in Children with Allergic Asthma. ( 28480606 )
2017
46
Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma. ( 28890845 )
2017
47
Efficacy of a leukotriene receptor antagonist for pediatric cedar pollen allergy complicated by asthma. ( 28928804 )
2017
48
Persistent asthma phenotype related with late-onset, high atopy, and low socioeconomic status in school-aged Korean children. ( 28231776 )
2017
49
Association of atopy phenotypes with new development of asthma and bronchial hyperresponsiveness in school-aged children. ( 28364972 )
2017
50
I^2-Adrenoceptor Function in Asthma. ( 28950943 )
2017